Randomized Surgical Adjuvant Trial of Interferon Alfa-n1 in Recurrent Papillomatosis

Brigid G. Leventhal, Haskins K. Kashima, Philip W. Weck, Phoebe Mounts, John K. Whisnant, Keith L. Clark, Seymour Cohen, Herbert H. Dedo, Donald J. Donovan, Blair W. Fearon, Linda J. Gardiner, Rodney P. Lusk, Harlan R. Muntz, Mark A. Richardson, George T. Singleton, Anthony James Yonkers, Diane Wold

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Sixty-six patients with recurrent respiratory papillomatosis of juvenile onset were treated for six months with interferon alfa-n1 (Wellferon) in a randomized crossover trial. Half received interferon alfa-n1 intramuscularly at a dosage of 5 megaunits per square meter daily for 28 days and then thrice weekly for five months, followed by six months of observation. The other half were observed for six months and then treated. Operations were performed every two months to assess disease extent by a scale developed for this purpose. The score for the patients during the first observation period was stable. There was a statistically significant lowering of score in patients receiving interferon alfa-n1 during both periods of drug administration. Eight of 57 patients with assessable airway disease achieved complete remission, as did one additional patient with disease limited to the nasopharynx. No patients achieved complete remission during six months of observation alone. This difference was statistically significant. Patients without tracheostomy were significantly more likely to achieve remission than those with a tracheostomy. The patients who were observed after discontinuation of the drug therapy showed a significant rise in score within four months. Symptoms of toxicity included transient fever, fatigue, nausea, and headache. Elevations in serum aspartate aminotransferase levels occurred in 64% of the patients. There was an inverse correlation between age and the ability to tolerate the medication. The dose studied may be close to the maximum tolerated dose. It appears that interferon alfa-n1 as an adjuvant to routine surgical management is effective in slowing the growth of respiratory papillomas.

Original languageEnglish (US)
Pages (from-to)1163-1169
Number of pages7
JournalArchives of Otolaryngology--Head and Neck Surgery
Volume114
Issue number10
DOIs
StatePublished - Jan 1 1988

Fingerprint

Papilloma
Tracheostomy
Observation
interferon alfa-n1
Maximum Tolerated Dose
Nasopharynx
Aspartate Aminotransferases
Cross-Over Studies
Nausea
Fatigue
Headache
Fever
Drug Therapy
Growth
Serum

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Leventhal, B. G., Kashima, H. K., Weck, P. W., Mounts, P., Whisnant, J. K., Clark, K. L., ... Wold, D. (1988). Randomized Surgical Adjuvant Trial of Interferon Alfa-n1 in Recurrent Papillomatosis. Archives of Otolaryngology--Head and Neck Surgery, 114(10), 1163-1169. https://doi.org/10.1001/archotol.1988.01860220097032

Randomized Surgical Adjuvant Trial of Interferon Alfa-n1 in Recurrent Papillomatosis. / Leventhal, Brigid G.; Kashima, Haskins K.; Weck, Philip W.; Mounts, Phoebe; Whisnant, John K.; Clark, Keith L.; Cohen, Seymour; Dedo, Herbert H.; Donovan, Donald J.; Fearon, Blair W.; Gardiner, Linda J.; Lusk, Rodney P.; Muntz, Harlan R.; Richardson, Mark A.; Singleton, George T.; Yonkers, Anthony James; Wold, Diane.

In: Archives of Otolaryngology--Head and Neck Surgery, Vol. 114, No. 10, 01.01.1988, p. 1163-1169.

Research output: Contribution to journalArticle

Leventhal, BG, Kashima, HK, Weck, PW, Mounts, P, Whisnant, JK, Clark, KL, Cohen, S, Dedo, HH, Donovan, DJ, Fearon, BW, Gardiner, LJ, Lusk, RP, Muntz, HR, Richardson, MA, Singleton, GT, Yonkers, AJ & Wold, D 1988, 'Randomized Surgical Adjuvant Trial of Interferon Alfa-n1 in Recurrent Papillomatosis', Archives of Otolaryngology--Head and Neck Surgery, vol. 114, no. 10, pp. 1163-1169. https://doi.org/10.1001/archotol.1988.01860220097032
Leventhal, Brigid G. ; Kashima, Haskins K. ; Weck, Philip W. ; Mounts, Phoebe ; Whisnant, John K. ; Clark, Keith L. ; Cohen, Seymour ; Dedo, Herbert H. ; Donovan, Donald J. ; Fearon, Blair W. ; Gardiner, Linda J. ; Lusk, Rodney P. ; Muntz, Harlan R. ; Richardson, Mark A. ; Singleton, George T. ; Yonkers, Anthony James ; Wold, Diane. / Randomized Surgical Adjuvant Trial of Interferon Alfa-n1 in Recurrent Papillomatosis. In: Archives of Otolaryngology--Head and Neck Surgery. 1988 ; Vol. 114, No. 10. pp. 1163-1169.
@article{d886f99357da45f786e5e25837832ebe,
title = "Randomized Surgical Adjuvant Trial of Interferon Alfa-n1 in Recurrent Papillomatosis",
abstract = "Sixty-six patients with recurrent respiratory papillomatosis of juvenile onset were treated for six months with interferon alfa-n1 (Wellferon) in a randomized crossover trial. Half received interferon alfa-n1 intramuscularly at a dosage of 5 megaunits per square meter daily for 28 days and then thrice weekly for five months, followed by six months of observation. The other half were observed for six months and then treated. Operations were performed every two months to assess disease extent by a scale developed for this purpose. The score for the patients during the first observation period was stable. There was a statistically significant lowering of score in patients receiving interferon alfa-n1 during both periods of drug administration. Eight of 57 patients with assessable airway disease achieved complete remission, as did one additional patient with disease limited to the nasopharynx. No patients achieved complete remission during six months of observation alone. This difference was statistically significant. Patients without tracheostomy were significantly more likely to achieve remission than those with a tracheostomy. The patients who were observed after discontinuation of the drug therapy showed a significant rise in score within four months. Symptoms of toxicity included transient fever, fatigue, nausea, and headache. Elevations in serum aspartate aminotransferase levels occurred in 64{\%} of the patients. There was an inverse correlation between age and the ability to tolerate the medication. The dose studied may be close to the maximum tolerated dose. It appears that interferon alfa-n1 as an adjuvant to routine surgical management is effective in slowing the growth of respiratory papillomas.",
author = "Leventhal, {Brigid G.} and Kashima, {Haskins K.} and Weck, {Philip W.} and Phoebe Mounts and Whisnant, {John K.} and Clark, {Keith L.} and Seymour Cohen and Dedo, {Herbert H.} and Donovan, {Donald J.} and Fearon, {Blair W.} and Gardiner, {Linda J.} and Lusk, {Rodney P.} and Muntz, {Harlan R.} and Richardson, {Mark A.} and Singleton, {George T.} and Yonkers, {Anthony James} and Diane Wold",
year = "1988",
month = "1",
day = "1",
doi = "10.1001/archotol.1988.01860220097032",
language = "English (US)",
volume = "114",
pages = "1163--1169",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Randomized Surgical Adjuvant Trial of Interferon Alfa-n1 in Recurrent Papillomatosis

AU - Leventhal, Brigid G.

AU - Kashima, Haskins K.

AU - Weck, Philip W.

AU - Mounts, Phoebe

AU - Whisnant, John K.

AU - Clark, Keith L.

AU - Cohen, Seymour

AU - Dedo, Herbert H.

AU - Donovan, Donald J.

AU - Fearon, Blair W.

AU - Gardiner, Linda J.

AU - Lusk, Rodney P.

AU - Muntz, Harlan R.

AU - Richardson, Mark A.

AU - Singleton, George T.

AU - Yonkers, Anthony James

AU - Wold, Diane

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Sixty-six patients with recurrent respiratory papillomatosis of juvenile onset were treated for six months with interferon alfa-n1 (Wellferon) in a randomized crossover trial. Half received interferon alfa-n1 intramuscularly at a dosage of 5 megaunits per square meter daily for 28 days and then thrice weekly for five months, followed by six months of observation. The other half were observed for six months and then treated. Operations were performed every two months to assess disease extent by a scale developed for this purpose. The score for the patients during the first observation period was stable. There was a statistically significant lowering of score in patients receiving interferon alfa-n1 during both periods of drug administration. Eight of 57 patients with assessable airway disease achieved complete remission, as did one additional patient with disease limited to the nasopharynx. No patients achieved complete remission during six months of observation alone. This difference was statistically significant. Patients without tracheostomy were significantly more likely to achieve remission than those with a tracheostomy. The patients who were observed after discontinuation of the drug therapy showed a significant rise in score within four months. Symptoms of toxicity included transient fever, fatigue, nausea, and headache. Elevations in serum aspartate aminotransferase levels occurred in 64% of the patients. There was an inverse correlation between age and the ability to tolerate the medication. The dose studied may be close to the maximum tolerated dose. It appears that interferon alfa-n1 as an adjuvant to routine surgical management is effective in slowing the growth of respiratory papillomas.

AB - Sixty-six patients with recurrent respiratory papillomatosis of juvenile onset were treated for six months with interferon alfa-n1 (Wellferon) in a randomized crossover trial. Half received interferon alfa-n1 intramuscularly at a dosage of 5 megaunits per square meter daily for 28 days and then thrice weekly for five months, followed by six months of observation. The other half were observed for six months and then treated. Operations were performed every two months to assess disease extent by a scale developed for this purpose. The score for the patients during the first observation period was stable. There was a statistically significant lowering of score in patients receiving interferon alfa-n1 during both periods of drug administration. Eight of 57 patients with assessable airway disease achieved complete remission, as did one additional patient with disease limited to the nasopharynx. No patients achieved complete remission during six months of observation alone. This difference was statistically significant. Patients without tracheostomy were significantly more likely to achieve remission than those with a tracheostomy. The patients who were observed after discontinuation of the drug therapy showed a significant rise in score within four months. Symptoms of toxicity included transient fever, fatigue, nausea, and headache. Elevations in serum aspartate aminotransferase levels occurred in 64% of the patients. There was an inverse correlation between age and the ability to tolerate the medication. The dose studied may be close to the maximum tolerated dose. It appears that interferon alfa-n1 as an adjuvant to routine surgical management is effective in slowing the growth of respiratory papillomas.

UR - http://www.scopus.com/inward/record.url?scp=0023715833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023715833&partnerID=8YFLogxK

U2 - 10.1001/archotol.1988.01860220097032

DO - 10.1001/archotol.1988.01860220097032

M3 - Article

VL - 114

SP - 1163

EP - 1169

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 10

ER -